º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM
¶}³oÓª©¤D¦³·P©ó
Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×z
Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O
¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P
©Ò¥H , ³oÓª©
¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï
§Æ±æ¼ö¾x¬Oì«h
¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý
¬ß±æ
¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú̪º¦@¦Pµ§°O
¡yÅý§Ṳ́@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O
´Á«Ý±zªº°Ñ»P
ÁÂÁ¤j®a!
SYNEURX LIFESCIENCE
¦p¦¹¬Ý¨ÓÀ³¸Ó¬O±ÂÅv¤è±½Íªº¤w¸g®t¤£¦h¤F......
¦~©³¼W¸êªº¤è¦¡ì¨Ó¬O±ÂÅv
¤£ª¾¹D³o¼Ë¸ÑŪ¦³µL¿ù»~..........
µo¨¥¤H «¸§Ó¿« µo¨¥¤H¾ºÙ °ÆÁ`¸g²z µo¨¥¤H¹q¸Ü 02-77422699
¥D¦®
¤½§i¥»¤½¥q¸³¨Æ·|¨Mij108¦~²Ä¤@¦¸ªÑªFÁ{®É·|¥l¶}¨Æ©y
²Å¦X±ø´Ú ¡@²Ä 32 ´Ú ¨Æ¹êµo¥Í¤é 107/12/31
»¡©ú
1.¸³¨Æ·|¨Mij¤é´Á:107/12/31
2.ªÑªFÁ{®É·|¥l¶}¤é´Á:108/02/27
3.ªÑªFÁ{®É·|¥l¶}¦aÂI:·s¥_¥«¦Á¤î°Ï·s¥x¤¸ô¤@¬q97¸¹4¼Ó(B´É»·¶¯U-Town±µ«Ý¤¤¤ß)
4.¥l¶°¨Æ¥Ñ:
(¤@)°Q½×¨Æ¶µ
(1)¸Ñ°£¸³¨ÆÄv·~¨î®×
(2)±ÂÅv¸³¨Æ·|ñq±M§QÅv±ÂÅv®×
(¤G)Á{®É°Êij
(¤T)´²·|
5.°±¤î¹L¤á°_©l¤é´Á:108/01/29
6.°±¤î¹L¤áºI¤î¤é´Á:108/02/27
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL
µo¨¥¤H «¸§Ó¿« µo¨¥¤H¾ºÙ °ÆÁ`¸g²z µo¨¥¤H¹q¸Ü 02-77422699
¥D¦®
¤½§i¥»¤½¥q¸³¨Æ·|¨Mij´£½ÐªÑªF·|±ÂÅv»P
SyneuRx Neuroscienceñq±M§QÅv±ÂÅv«´¬ù
²Å¦X±ø´Ú ¡@²Ä 43 ´Ú ¨Æ¹êµo¥Í¤é 107/12/31
»¡©ú
1.¨Æ¹êµo¥Í¤é:107/12/31
2.¤½¥q¦WºÙ:SyneuRx Neuroscience
3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):SyneuRx Neuroscience¤½¥q¬°¥»¤½¥qÃö«Y¥ø·~
¤§¥S§Ì¤½¥q¡At³d¤H§d¶®¬Â¤k¤h¬°¥»¤½¥q¸³¨Æªø¤§°t°¸¡C
4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î
5.µo¥Í½t¥Ñ:¥»¤½¥q¸³¨Æ·|¨Mij¡A¬°¥[±j¸ó°êÀç¹B¡A´£½ÐªÑªF·|±ÂÅv¥»¤½¥q»PÃö«Y¥ø·~
SyneuRx Neuroscienceñq±M§Q±ÂÅv«´¬ù¡A±ÂÅv©Ò¦³¶W¯Å¥é»sÃĤÎÁ{§É¹êÅç¤G/¤T´Á
¬ãµoÃĪ«¬ÛÃö±M§Q(Programs in supergenerics and phases II/III pipeline) ¡C
¥BSyneuRx Neuroscience¥Ñ¥»¤½¥q±ÂÅv±M§Q¶µ¥Ø©Ò¨ú±o¤§¦¬¯q¡A¦©°£¦æ¬F¶O¥Î¤§«á¡A
±N¥þ¼Æªð¦^¥»¤½¥q¡C
6.¦]À³±¹¬I:µL
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:
(1)¥»®×¯A¤ÎÃö«Y¤H¥æ©ö¡A±ÂÅv«´¬ù«Ý¥»¤½¥qªÑªFÁ{®É·|³q¹L«á¤è¥Í®Ä¡C
Estimated Enrollment : 348 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Actual Study Start Date : March 29, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : June 30, 2019
-----------------------------------------------------------------------------------------------
¨Ì·Ó¹wp§¹¦¨¤éEstimated Primary Completion Date : December 31, 2018
´Á¬ßªñ´Á¤½¥q´£¨Ñ³Ì·s·sÃĶi«×¸ê°T...
¨Ó·½¡GÃÄ´ç ¡@2018-12-25
med.sina.com/article_detail_103_2_58059.html
. ¿z¿ïªºÃþ«¬
. ¿@«×-ÅTÀ³¦±½u©MIC50
. ¡§±`¼Æ¡¨Ãþ«ü¼Ð: Kd ¡BKi¡BKB¡BKA¡BKm
. ³Ì¤jµ²¦X¦ìÂI¼ÆBmax
. ¥b³Ì¤j®Ä¯à¿@«×»P®Ä¯à¡GEC50 & Emax
. ¿E°Ê¾¯¡B³¡¤À¿E°Ê¾¯¡B«ú§Ü¾¯¡BÅܺc½Õ¸`¾¯¥H¤Î¤Ï¦V¿E°Ê¾¯
. Àx³Æ¨üÅé
. Á`µ²
¤Æ¦Xª«ªºÅé¥~¿z¿ï¬OÃĪ«¶}µo³Ì°_©l¤]¬O«D±`«nªº¤@Ó¶¥¬q¡A¡§ÅªÀ´¡¨´ú¸Õ¼Æ¾Ú¬O¨Mµ¦ªº°ò¥»±ø¥ó¡A¥u¦³¦UÓ«ü¼Ð¦b¤@Ó¦X²zªº°Ï¶¡¤º¤~¨ã¦³¶i¦æ¶i¤@¨BÀu¤Æªº»ùÈ¡C
¨Ó·½¡GÂåÃÄÅ]¤è ¡@2018-12-25
med.sina.com/article_detail_103_2_58054.html
¨Ó·½¡GÂåÃÄÅ]¤è ¡@2018-12-25
med.sina.com/article_detail_103_2_58054.html
Date:
December 13, 2018
Source:
University of North Carolina Health Care
www.sciencedaily.com/releases/2018/12/181213142112.htm
Won¤Î¨ä¦P¨Æªí©ú¡A³o¨Ç°ò¦]·|¼vÅT¥ý«eºë¯«¤Àµõ¯g¬ã¨s¤¤¯A¤Îªº¬ðIJ¡A¤A酰ÁxÆP¨üÅé¡AÂ÷¤l³q¹D©M¨ä¥L³~®|ªº¥\¯à¡C
¬ì¾Ç®aÌÁÙ½T©w¡Aºë¯«¤Àµõ¯g¥Dn¬O¯«¸g¤¸¯e¯f¡A¦Ó¤£¬O¨ä¥L¸£²ÓM¡C( The scientists also determined that schizophrenia is primarily a disorder of neurons, not of other brain cells. )
en.wikipedia.org/wiki/Neuron
½²±Ð±Â±M¤å
Glutamatergic mechanisms in schizophrenia
¦¨¬°SND-11 ~ SND-13 ¾÷Â઺²z½×°ò¦
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a !
1.¼W¸ê
2.IPO
3.±ÂÅv
·íµM¥H±ÂÅv¤è¦¡³Ì¨ü¥«³õÅwªï
FDAµ¹ªºBTD ¬JµM¤£¯à§l¤Þ¥xÆW¥«³õªº²´¥ú , ´N¥u¦³¾a¤j¼tªº¼z²´¤F
µL²á¤§¨¥
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a !
¨Ó·½¡GÂåÃÄÅ]¤è ¡@2018-12-13 09:58
med.sina.com/article_detail_100_2_57451.html
¦bªüº¸¯ý®üÀq¯f»â°ì¡A¨S¦³¥ô¦ó¤@®a¤½¥q¾D¹Jªº¥¢§Q¯à¤ñ§¨Ó§óºGµh¡C¦ý¬O¡A³o¨Ã¤£ªýê³oÓ»sÃÄ¥¨¤H¦A¦¸¤Uª`ªüº¸¯ý®üÀq¯f¸ê²£¡A¨Ãñq¤@¶µÁ`ÃB20»õ¬ü¤¸ªº¥æ©ö¡C
§¨Ó³o¦¸»PAC Immune¤½¥q¦X§@¶}µoªº®Ö¤ß¸ê²£¬O¤@´Ú¥N¸¹¬°ACI-3024ªºÃĪ«¡A³B©óÁ{§É«e¶¥¬q¡C
AC Immune ¤½¥q12¤ë12¤é¦¤W©ÜÅS¡A»P§¨Ó¹F¦¨¤F·sªº¦X§@¡AÀò±o8000¸U·ç¤hªk¦º¥I´Ú¡A6000¸U·ç¤hªk¦¤¤´Á¨½µ{ª÷¡A¨ä¥L17»õ¬ü¤¸ªº¬ãµo¡Bµù¥U¤Î¤W¥«¨½µ{ª÷¡C²£«~¤W¥««á¡AAC Immune¥iÀò±o§CÂù¦ì¼Æªº¾P°â¤À¦¨¡C
www.chinatimes.com/realtimenews/20181212002085-260405
¥x¤jÂå°|¯«¸g³¡¥D¥ô§d·ç¬ü«ü¥X¡AY¬O¤Úª÷´Ë¯f©µ»~ªvÀø¡A®£·|¥[³t¥¢¥h¦æ°Ê(¥¢¯à)¡Bªí¹F¯à¤Oªº³t«×¡A¼W¥[¦X¨Ö¥¢´¼»P¼~Æ{¯g(¥¢¤ß)ªº¡u4¥¢¡v·ÀI¡C
¥D¦]¬O¤Úª÷´Ë¯fªº¸£³¡¥\¯à·l¶Ë¤£¥i°f¡A¦pªG¨S¦³¤Î¦µo²{¡BªvÀø¡A±N·|¥[§Ö±wªÌ¥X²{°Ê§@»Ùê¡B³à¥¢¦æ°Ê¯à¤Oªº®É¶¡¡A¤]·|³y¦¨±wªÌ¥¢¥h¤f»yªí¹F¯à¤O¡C¾Ú²Îp¡A¬ù2¦Ü3¦¨±wªÌ¿©¯f±ß´Á·|¥X²{¥¢´¼°ÝÃD¡A§ó¦³43¢H¯f±w·|¦]¯e¯f´c¤Æ¦Ó¨Öµo¼~Æ{¯g¡C
(Ãþ¦ü©ó¥xÆWªº¤jªÑªF©M¸³ºÊ¨Æªº³W½d)
¸T°â³W©w
5.1 ¡m¥DªO³W«h¡n²Ä 10.07(1)±ø¡]¡m³Ð·~ªO³W«h¡n²Ä 13.16A(1)±ø¡^q©ú¡A°£¤W¥«¤å¥ó¤º´£¤Îªº°âªÑ¥~¡A¦bµo¦æ¤H¥Ó½Ð¤W¥«®É¥Zµoªº¤W¥«¤å¥ó¦C¬°µo¦æ¤H±±ªÑªÑªFªº¤H¤h©Î¤@²Õ¤H¤h¤£±o¡G
(a) ¦Û¤W¥«¤å¥ó¤¤©ÜÅS±±ªÑªÑªF«ù¦³ªÑÅv·í¤é°_¦Ü
¤W¥«¤é´Á°_pº¡ 6 Ӥ뤧¤é´Á¤î´Á¶¡¡]¡uº¤»Ó¤ë´Á¶¡¡v¡^¥X°âªÑ¥÷¡F¤Î
(b) ¦bº¤»Ó¤ë´Á¶¡©¡º¡·í¤é°_pªº 6 Ӥ뤺¡]¡u²Ä¤GÓ¤»Ó¤ë´Á¶¡¡v¡^¥X°âªÑ¥÷¡A
¥HP¸Ó¦W¤H¤h©Î¸Ó²Õ¤H¤h¦b¥X°âªÑ¥÷«á¤£¦A¦¨¬°±±ªÑªÑªF ¡C
3 ¡u±±ªÑªÑªF¡vªº©w¸q¤ÎÄÀ¸q
¬ÛÃö¡m¤W¥«³W«h¡n±ø¤å
3.1 ¡m¥DªO³W«h¡n²Ä 1.01 ±ø¡]¡m³Ð·~ªO³W«h¡n²Ä 1.01 ±ø¡^©w¸q¡u±±ªÑªÑªF¡v¬°:
(i) ¥ô¦ó¦³Åv¦bµo¦æ¤HªºªÑªF¤j·|¤W¦æ¨Ï©Î±±¨î¦æ¨Ï 30%¡]©Î¡m¤½¥q¦¬ÁʤΦX¨Ö¦u«h¡n¤£®É³W©w·|IJµo±j¨î©Ê¤½¶}n¬ù©Ò»Ýªº¨ä¥L¦Ê¤À¤ñ¡^©Î 30% ¥H¤W§ë²¼Åvªº¤H¤h©Î¤@²Õ¤H¤h¡F©Î
(ii) ¦³¯à¤O±±¨î²Õ¦¨µo¦æ¤H¸³¨Æ·|ªº¤j³¡¤À¦¨ûªº¤H¤h©Î¤@²Õ¤H¤h ¡C
ºK¦Û att.hkex.chinalaw.com/tr_9291_11382.pdf
Y¦³×¥¿ªº·sª© ½Ð§ó¥¿
ÁÂÁ¤j®a!
www.berich.com.tw/Rproject/DP/TalkTalk/Talk_Detail.asp?ii=696&CNpg=1
·|û¡Ggaster8000 µoªí®É¶¡:2005/8/31 ¤U¤È 09:17:58²Ä 26 ½g¦^À³
4. IPO«áªѪF¶·¸g180¤Ñ³¬Âê´Á«á©l¯à½æ¥X
¤W±³oÂI§Úı±o«Ü«n¡A¬On¸òÀH®ü¥~¤W¥«ªºªÑªF»Ýnª`·Nªº
³o¬O¬ü°ê¹L¥hªºª¬ªp¡A²{¦bªk¥O¬O§_¦³§ó§ï§Ú´N¤£ª¾¹D¤F
¤Ï¥¿®É¶¡Á٫ܤ[¡A¤ß®®¤]¤£¤@©w·|¤U¿³ÂdÂà®ü¥~IPO
¥¼¨ÓÂà®ü¥~IPO¤]¤£¤@¥u¦³¤ß®®³o¤@ÀɪѲ¼
§Ú§ä¨ìªº¸ê®Æ´N©ñ¤W¨Ó¤À¨É¡A¦³®É¶¡¥i¥H§â©_´ºªº°Q½×¦ê¬Ý¹L¡A³o¨Ç³£¬OÄÝ©óÃB¥~ªºª¾ÃÑ
¦U®aÀç·~û¤]¤£¤@©w«Ü±M·~¡A¥i¯à°Ý¤£¨ì
´¿¸g¡A§Ú¸ß°Ý¦U®aÃÒú³°Ó½Æ©e°U®ü¥~³øµ|°hµ|ªí®æ°ÝÃD¡A¤]³£Âà¤F¦n³q¹q¸Ü¤~°Ý¨ì......
¦b®ü¥~IPOªºµ|°È°ÝÃD¯uªº¬O³Â·Ð...¦Ó¥B¯Ó¶O®É¶¡¸û°ê¤ºIPOªø...
¤£½×¦bþIPO...
¦ý¤j®a·Q¥²³£¬O»{¦P¤ß®®ªº·sÃÄ¥«³õ¼ç¤O¥H¤Î¬ãµo¯à¤O¤~·|ªø´Á§ë¸ê...
´Á¬ß¤½¥q¦h¤À¨É·sÃĶi«×¸ê°T...§l¤Þ§ó¦h¥«³õ§ë¸ê¤H...
¥H¤W~~¨Ñªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ
¤j®a±q¤£¦P¨¤«×¥Xµo , «Øºc¤@Ó¶°«ä¼s¯qªº¥¥x , ±N¦UºØª¬ªpªº§Q¹ú±o¥¢§e²{ , ¹F¤¬¬Û¥æ¬y ¬Û¤¬¾Ç²ßªº¾÷·|
Åý¤j®a¥i¥H¦p¤p³ì¤jªººc·Q --- ·Q¯d·Q¨«ªºªÑªF³£¥i¥H¦³©ÒÂkÄÝ
©Ò¥H«Ø½Ð¤½¥qY¦³©Ò¸¡®× , ½ÐºÉ§Ö¿ì²z¤@À³µ{§Ç , ¤½§i¶gª¾
¨Ãµ¹¤j®a¦³¨¬°÷ªº®É¶¡ , ±q®e¦a¤W¤U¨® , »«¥D³£¯àºÉÅw
ÁÂÁ¤j®a!
¨ä¥¦¤H¦CÁ|¦b¥xÆW¤W¥«ªº¬Ýªk,
³£¬O¹ú¤j©ó§Qªº,¥ú´NÄw¸ê¨Ó¬Ý,¦b¥xÆW¹ï¥Í§Þ¦p¦¹¤£¤Íµ½Àô¹Ò,¥u·|¦Û°QW¦Y
´`¥H©¹©_´º¼Ò¦¡,©¹®ü¥~IPO,ªÑªFµ¥¤ñ¨Ò´«ªÑ,·Q¯d·Q¨«ªºªÑªF³£¥i¥H¦³©ÒÂkÄÝ
¦p²q·Q¤j©Ò¨¥,Äw¸ê»PIPO³sµ²,ºÉ§Ö§ä¨ì¿ú±N¨ä¥¦pipelines ¶}©lÁ{§É,¤~¬O²Å¦XªÑªF³Ì¤j§Q¯q
½²¸³¦bªÑªF·|»¡ªº¤GÂIÃö©ó¸ê¥»¥«³õªº¬Ýªk«Ü«n,¦³¥hªº¤H¤£¥é¦^·Q¤@¤U
¥i¥H±q¥H¤W¤GÂI«ä¯Á¸³¨Æªøªº¬Ýªk
Á`¤§,¨«¥X¥h,¤~¬Ý±o¨£¥@¬É¤§¤j
°²¦p¯à¦b¥xÆW¤W¥«Âd·íµM³Ì¦n¡A¥i¥H¬Ù¥h®ü¥~©Ò±oªº³Â·Ð
¦ý¬O±N¬ãµo¡B°]°È¥D¤O½Õ©¹»´ä¤ß®®¡A¦Ó¤£¬O¬°¤F¨ì»´ä¤W¥«¡A³o´N¶W¥GÓ¤HÅÞ¿è©Ò¯à§PÂ_¤F
ÁÂÁ¤j®a¡I
ªÑªF«ùªÑ°÷¦h¤]«Ü¤Ö¤£¤¶¤J¸gÀçÅvªº
¦³¤@ÀɧڦbÆ[¹îªº¥¼¤W¥«¤½¥q´I¥Ð¹q¾÷¸³¨Æªø´N¦b©ê«èªÑªF¤¤¿û¤¶¤J¸gÀç
www.chinatimes.com/newspapers/20150819000039-260202
¤¤¿û·í¤W´I¥Ð¹q¾÷ªÑªF«á´NÅý¸³¨Æªø«Ü«á®¬
¸³¨Æªø¦b³o½g·s»D©ê«è»¡
¤¤¿ûºX¤Uªº¤¤¬Õ§ë¸ê¡A¥h¦~§¹¦¨¤JªÑ´I¥Ðªº²Ä2¤Ñ´N¶}¥X±ø¥ó¡A¡u¸³¨Æªø¤£·|´«¤H¡A¦ý°]°Èªø»P·|p®v¨Æ°È©Ò³£nºM´«¡v¡C±iª÷¾WÁöµM²n§ÖµªÀ³¡A¦ýÅý¥L®ðµ²ªº¬O¡A¡u¤¤¿û¬£¾nªº°]°È¥DºÞ¸gÅ礣¨¬¡A¥uÀ´¦¨¥»·|p¡A«o¨Ý°]°È³¡»PºÞ²z³¡°ÆÁ`¡A´I¥Ðû¤u«Ü¤£ªA³o¦ì¥DºÞªº¾Ç¸g¾ú¡v¡B¡u³o¦ì°]°È¥DºÞ¤£À´Â¾³õÛ²z¡A»â´I¥ÐªºÁ~¤ô¡A«o¨Æ¨Æ³£¦V¤¤¿û³ø§i¡v¡C
½²¸³¨Æªøªº20%ªÑ¥÷¤]·|¦A³Qµ}ÄÀ
·d¤£¦n·|¹³¥_·¥¬P¤@¼Ë
¶}¤@ӪѪF·|¸gÀçÅv´N³Q®³¨«
¸³¨Æªøn´«¤H°µÅo......
·PÁ±zªº«ü±Ð»P«ü¾É
±z©Ò¦CÁ|ªº´ä¥æ©Ò¤å¥óªñ200¶ ¡A¤p§Ì®£®ø¤Æ¤£¨}¡A±¾¤@º|¸UÀ³¬°±`ºA
¥xÆW¤ß®®n©¹þ¨à±¾µP ¡A¤½¥q©|¥¼¤½§i ¡A¤p§Ì¬O«ù¶}©ñªººA«×
¤p§Ì«e½g¨Ì11/28¤½¥q«¤j·s»Dªº²q´ú ¡A¤]¶È¬OÓ¤Hªº¤@ºØ²q´ú ¡AµLÃö¥G¤½¥qªº¨Mµ¦
¸Ó«¤j·s»D¤½¥q±N¬ãµo°ÆÁ`¤Î°]°È¸g²z½Õ©¹»´ä¤ß®® ¡A·íµM¬O¤p§Ì²q´ú«e¶i»´äªº¥Dn¨Ì¾Ú
·í®É ¡A¤p§Ì¬O·Q
Y¤½¥q±N¥xÆW¤ß®®§@¬°Àç¹B¥DÅé ¡A«h¯d¦b¥xÆW ©Î«e©¹¬ü°ê »´ä ¡A³£¥i«O«ùµÛ¼u©Ê ; ±N¥Dn¤Hû½Õ¥ô»´ä¤ß®® ¡A¦ü¥G¤£¦X¦¹ÅÞ¿è ? ¦¹¨ä¤@¤]
¤S±z©Ò´£ªº [ Àç¹B¸êª÷ ] ¤Î [ ±M·~§ë¸ê¤H ] ªº°ÝÃD
¹ï©ón«e©¹»´äªº¤½¥q À³¤£¬O¤@ºØ¤£©ö¸Ñ¨Mªº°ÝÃD ¡A¸Õ·Q³s¤W¥««eªº±M·~§ë¸ê¤Hªº§ë¸ê³£·d¤£©w ¡A¤S«ç¯à¤W¥«¥h¶Ò±o¸êª÷©O ?
³o¨â¶µ¡A´ä¥æ©Ò°µ³o¼Ëªº³W½d :
<<<
¾A¥Î©ó¥Íª«¬ì§Þ¤½¥qªº¤W¥«±ø¥ó
18A.02 ®Ú¾Ú¥»³¹¥Ó½Ð¤W¥«ªº¥Ó½Ð¤H¡A°£¥»³¹ªº³W©w¥~¡A¥ç¶·²Å¦X¡m¤W¥«³W«h¡n²Ä¤K³¹¡]²Ä 8.05 ±ø°£¥~¡^ªº³W©w¡C
18A.03 ®Ú¾Ú¥»³¹¥Ó½Ð¤W¥«ªº¥Ó½Ð¤H¥²¶·¡G¡X
(1) ¦V¥»¥æ©ö©ÒÃÒ©ú¨Ã¥O¨ä½T«H¥Ó½Ð¤H¦X¸ê®æ¤Î¾A¦X¥H¥Íª«¬ì§Þ¤½¥qªº¨¥÷¤W ¥«¡F
(2) ¤W¥«®Éªº¥«È¦Ü¤Ö¹F 15 »õ´ä¤¸¡F
(3) ¦b¤W¥««e¤w¥Ñ¤jP¬Û¦PªººÞ²z¼h¸gÀç²{¦³ªº·~°È¦Ü¤Ö¨âÓ·|p¦~«×¡F¤Î
(4) ½T«O¥Ó½Ð¤H¦³¥R¨¬ªºÀç¹B¸êª÷¡]¥]¬Ap¤J·s¥Ó½Ð¤Hº¦¸¤W¥«ªº©Ò±o´Ú¶µ¡^¡A¨¬¥iÀ³¥I¶°¹Î¥Ñ¤W¥«¤å¥ó¥Zµo¤é´Á°_p¦Ü¤Ö¤Q¤GÓ¤ë©Ò»Ý¶}¤äªº¦Ü¤Ö 125%¡C
¸Óµ¥¶}¤äÀ³¥Dn¥]¬A¡G (a) ¤@¯ë¡B¦æ¬F¤ÎÀç¹B¶}¤ä¡]¥]¬A¥ô¦ó¥Í²£¦¨¥»¡^¡F¤Î (b) ¬ãµo¶}¤ä¡C
µù 1¡G ¥»¥æ©ö©Ò¹w´Áµo¦æ¤H·|±Nº¦¸¤W¥«©Ò±o´Ú¶µ¤j³¡¤À¥Î©ó¤ä¥I¤Wz¶}¤ä¡C
µù 2¡G «ö¥»±øpºâ©Ò»ÝÀç¹B¸êª÷®É¥i¤ð¶·p¤J¸ê¥»¶}¤ä¡A¦ýY¸ê¥»¶}¤ä¬O¨Ó¦Û É´Ú¡A¬ÛÃöªº§Q®§¤ÎÁÙ´Ú±¡ªp«h¶·pºâ¦b¤º¡C
¤Î
85. ¾¨ºÞÁp¥æ©Ò°ò©ó¤Wzì¦]¦Ó¤£ÀÀ¹ï¦p¦ó¬É©w¡u¸ê²`§ë¸êªÌ¡v¤Î¡u¬Û·í¼ÆÃBªº§ë¸ê¡v¶i¦æ ©ú½u´ú¸Õ¡A¦ý§ÚÌ¥ç»{¦P¦n¨Ç¦^À³¤H¤hªº·N¨£¡A´N¬O¦V¥«³õ´£¨Ñ¶i¤@¨B«ü¤Þ¤Î°ò·Ç¦³§U ¥«³õ¦³§ó²M´·ªº»{ÃÑ¡C¬°¦¹¡A
Áp¥æ©Ò¤@¯ë·|¡G
(a) ±N¡]¤U¦CÃþ§Oªº§ë¸êªÌµø¬°¸ê²`§ë¸êªÌªº¨Ò¤l¡]¶È§@»¡©ú¤§¥Î¡^¡G
(i)±MªùªºÂåÀø«O°·©Î¥Íª«¬ì§Þ°òª÷¡A©ÎºX¤U¦³±Mªù©Î°¼«©ó§ë¸ê¥Íª«»sÃÄ»â°ìªº¤À¤ä¡þ³¡ªùªº¤j«¬°òª÷¡F
(ii)¤j«¬ªº»sÃÄ¡þÂåÀø«O°·¤½¥q¡F
(iii)¤j«¬ªº»sÃĤ½¥q¡þÂåÀø«O°·¤½¥qªº·ÀI§ë¸ê°òª÷¡F¤Î
(iv) ºÞ²z¸ê²£Á`Ȥ£¤Ö©ó 10 »õ´ä¤¸ªº§ë¸êªÌ¡B§ë¸ê°òª÷©Îª÷¿Ä¾÷ºc¡F¤Î
(b) µø¤U¦C§ë¸êª÷ÃB¬°¡u¬Û·í¼ÆÃBªº§ë¸ê¡v¡A¥i§@«ü¼Ð°Ñ¦Ò¡G
(i) ´N¥«È¤¶¥G 15 »õ´ä¤¸¦Ü 30 »õ´ä¤¸ªº¥Ó½Ð¤H¦Ó¨¥¡A§ë¸êª÷ÃB¤£¤Ö©ó¥Ó½Ð¤H ¤W¥«®É¤wµo¦æªÑ¥»ªº 5%¡F
(ii) ´N¥«È¤¶¥G 30 »õ´ä¤¸¦Ü 80 »õ´ä¤¸ªº¥Ó½Ð¤H¦Ó¨¥¡A§ë¸êª÷ÃB¤£¤Ö©ó¥Ó½Ð¤H ¤W¥«®É¤wµo¦æªÑ¥»ªº 3%¡F¤Î
(iii) ´N¥«È¶W¹L 80 »õ´ä¤¸ªº¥Ó½Ð¤H¦Ó¨¥¡A§ë¸êª÷ÃB¤£¤Ö©ó¥Ó½Ð¤H¤W¥«®É¤wµo¦æªÑ¥»ªº 1%¡C
½Ðª`·N¡A¥»¬q©Òz¶È¬°§PÂ_¥Íª«¬ì§Þ¤½¥q¬O§_¾A¦X¤W¥«®É¦p¦óÂç©w¡u¸ê²`§ë¸êªÌ¡v¤Î¡u¬Û ·í¼ÆÃBªº§ë¸ê¡v¦Ó´£¨Ñªº«ü¤Þ¡C
>>>
¦AªÌ
¥R¨¬ªºÀç¹B¸êª÷¥]¬Ap¤J·s¥Ó½Ð¤Hº¦¸¤W¥«ªº©Ò±o´Ú¶µ¡A©Ò¥HÀ³µLª§Ä³
¤TªÌ
»´ä¤ß®®Á`¥«ÈÀ³¤£·|¥u¹F³Ì§C¼Ð·Çªº15»õ´ä¤¸ ¡An¥Î30»õ´ä¤¸ªº¼Ð·ÇÀ³¤]¤£¬OÃø¨Æ ?
¤S°·¥ÃÅv§Qª÷ ©M¤ß¬ùªº°ÝÃD
§Ú·Q
¨C®a¤½¥qªº²£«~ ¥«³õ°âÃB ±ÂÅv¹ï¶H³£¤£¤@¼Ë ¡AÅv§Qª÷²v©Î¦³¤£¦Pª¬ªp
±ÂÅv¹ï¶H¶V¤j©@ , Åv§Qª÷²v¥i¯à¶V§C , ´N§Ú¬Ý¹Lªº¸ê®Æ , ¬ù¦b18% ~ 32%(¤T´ÁÁ{§É¦Û¤v§¹¦¨ªº»ù½X , ¤£§t¤¤¸Î»PTHªº¦X¬ù)
¥«³õ°âÃB¨«°ª , Åv§Qª÷²v¤]·|¸òµÛ½Õ°ª , ¦³ªºÁÙ¦³¨½µ{ª÷
·íµM , ¨CÓӮ׳£¦³¦Û¤v¿W¥ßªº¯SÂI , Åv§Qª÷²v ¨½µ{ª÷¤£¯à¤@·§¦Ó½×
·íªì¤ß¬ùªº³]¥ß , ¤p§Ì¤]´¿´Nµ|tªºÆ[ÂI ²q´ú¦b¥x¤W¥«ªº¾÷·|¿@¤F
¦ý²{¦b¬Ý¨ì¤½¥q11/28ªº¤½§i , Åý§Ú¦b¥x¤W¥«ªº¬Ýªk²¤¦³°Ê·n
¤]³\¤ß¬ùªº³]¥ß , ¤]¥i¥u¦b©Ó±µ¥Ø«eÁÙ¦b«H°UªºªÑ²¼¦Ó¤w
¥t¥~®ü¥~©Ò±oªº°ÝÃD
ªº½T , ¦b¥xÆW¤W¥« , ´N©~¦í¦b¥xÆW±o§ÚÌ , ¥i¥H¬Ù«o¤@¨Ç³Â·Ð
³Ì¥DnÁÙ¬O®ü¥~©Ò±o½Òµ|ªº°ÝÃD --- ¸Ó¦~«×®ü¥~Àò§Q¶W¹L¥x¹ô670¸U , n¦©³Ì§Cµ|t20%
¨ìþÃäIPO , ¬O¤½¥q¿Å¶q½Ñ¦h¦]¯Àªº¨Mµ¦ , ÁÙ¦³¦h¼ÆªÑªFªº¨Mij , «D¨CÓÓ¤H©Ò¯à¼vÅT
µM¦n¼ÐªºÃø´M§r! Y¯uªº¨ì®ü¥~ IPO , Ãø¹D§ÚÌ´Nn¦]¬°¥²¶·Ãº¯Ç20% ªºµ|t¦Ó§âªÑ²¼½æ¤@½æ , ¤£ÁȤF¶Ü ? ¬Û«H±z§Ú³£¤£·|
´N¬O¦]¬°¥xÆW¥«³õ¹ï·sÃĪѯʥF»{ÃÑ , ¾ÉP¤£¤Ö¦³¼ç¤Oªº¤½¥q³QÄY«§C¦ô
n¬O§Ú̬O³o¨Ç¤½¥qªº¸gÀçªÌ , ®£©È¤]·|·Qn¥X¨« , Åý¥@¬É¬Ý±o¨£?!
¦Ü©ó¤j¤áªº°ÝÃD
Y¥L̦³°ÝÃD , ´N¤Ó¤p¬Ý¥L̤F
´CÅ餣¬O¦³³ø¾É°²¥~¸êªº¦s¦b¶Ü? ³o¤£¬Oµ|tªº¦Ò¶q¶Ü ?
°²³]¤ß®®¥¼¨Ó¥i¥H¦¨¥\ , ¨º¤j¤á·|«ç»ò°µ , ·íµM¬OÃþ¦ü¥xªÑ¥H«e¦³ÃÒ©Òµ|®Éªº°µªk , ¯E¹©ª©¥H«e°Q½×¬Æ¦h , ¦b¦¹¤£¦A¦h¼L
Á`¤§
¦b¤½¥q©|¥¼¤½§G¤§«e , ¥ô¦ó¤è®×³£¥i³Q²q´ú , ³£¦³¥i¯à
µM¥h¦~¦Ü¤µ , ¿ð¿ð¥¼¨£¤½¥q¼W¸ê , ¤½¥q©Î¦³¤@®M»PIPO¤@°_¦Ò¶qªºpµe§a!?
¥H½²±Ð±Â¹ïÁ{§É¥Î¤ß¤§²` ³W¹º¤§¦n
©ñ½Ñ°]°ÈpµeÀ³¸Ó¤]¥i¦p¬OÆ[ , ¤£¬O¶Ü!?
ÁÙ¬O¦Ñ¸Ü¤@¥y , ²q´ú´N¬O²q´ú , µLÃö¥G¨Æ¹ê , Åý§ÚÌÀRÔ¤½¥q¤½§i
ªÑ»ù¥Ñ¥«³õ¨M©w , ºÝ¬Ý¤j¤á«ç»ò¬Ý «ç»ò°µ !
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
ªÑ»ùÀò§Q¦³®tÃB¤£¥²Ãºµ|
¦ÓªÑ§Q·|¯Ç¤J©Ò±o¤¤¥t¥~¤]¦³°·«O¸É¥R«O¶O
www.businesstoday.com.tw/article-content-80405-164094
®ü¥~¦¬¤J¶·núµ|¡A»´ä¤W¥«³oÓ»Ýn¤F¸Ñ
www.moneydj.com/tax/content.djhtm?a=04-06
¦pªG¤ß®®»´ä¤W¥«¡A§ë¸êª÷ÃB¶W¹L¤d¸U¤¸¥H¤W¡A¶R½æªÑ²¼ªºÀò§Q¡A¶W¹L670¸U§Kµ|ÃBªº¤j¤á
·|¤ñ¥xªÑ¶R½æúµ|ú§ó¦h¡A©Ò¥H¹ï¤j¤á¨Ó»¡¤ß®®¯d¦b¥xÆW·|§ó¦³§Q
¥xÆW¤H¶R½æ¥xªÑ¡AÀò§Q¤£¥Î¯Ç¤Jºî©Òµ|
®ü¥~¦¬¤J¬O¶·n¥Ó³øúµ|ªº³á
¦b»´ä¤W¥«¡A¥Ó³ø®ü¥~Àò§Qªº®ÉÔ¶·¦Û¦æÁ|ÃÒ¥æ©ö¦¨¥»
¥Ó³ø©Ò±oµ|¡A§ó½ÆÂøn¦h§ó¦hªº¸ê®Æ
¨S¯d¦í²{¦b¿³Âd¥æ©ö¸ê®Æ¡Aµ¥¤U¿³Âd¡A®ü¥~IPO®É´Nª¾¹D³Â·Ð¤F
www.trpma.org.tw/index.php/tw/news/item/3726
°·¥Ã¦b¬ü°ê¥«³õ¦³¾÷·|¨ú±o¤T¨ì¥|¦¨ªº¾P°âÅv§Qª÷¤ñ«¡A¤j³°¤è±«h¬°8¨ì12%
³o«h·s»D°·¥Ã¯à®³¨ìªº´N³Q¦ô±o«Ü§C
³o´N¬O§Ú²q¥i¯àn¦Û¤v½æªºì¦]
¤ß®®ºë¯«¤Àµõ¯gSND¨t¦C¬O¦b¬ü°ê¡B¥[®³¤j¥H¤Î¼Ú¬w³Ì¦h40Ó¤¤¤ß¦¬®×¡A¤¤°ê¥«³õ¦³¥i¯àÁÙn°µ¾ô±µ¸ÕÅ礧Ãþªº
¸Ñª¼«á¤¤°ê¤W¥«ÁÙn¦n¤@¬q®É¶¡
¤¤°ê¤è±¤£ºÞÁ{§É©Î¾P°â¶·n«H¥ôªº°]·|¥DºÞ¨nµÛ¡An¤£µM«Ü®e©ö³Q°µ¤â¸}¡C
쥻Á{§É¸ÕÅ窺°e¥ó¡B»s¾¯»s³y¤Î¤j³°¥«³õ©Ý®i¡A¬O¥Ñ¤jªÑªF°·¨È³Wµe
°·¨È¤@ª½¥H¨Ó«÷©R½æªÑ²¼¡A©M¤ß®®¤j·§Ãö«Y¤]¤£·|«Ü¦n¤F
»´ä³]¥ß¤½¥qªº¥Øªº¤£·|¥u¦³¬O»´ä¤W¥«
¤U¤@¶¥¬q¬ãµo¥¢´¼¯gn¦V¤¤°êCFDA¥Ó½ÐÁ{§É¤G´ÁIND
¶·n©M¤¤°ê§óÀWÁcªº¥æ¬y
¥H«á¤j³°¥«³õªº©Ý®i´N·|¥ÑSyneuRx Neuroscience HK Ltd.¨Ó©Ó¾á
¤£·|¦A¸g¹L°·¨È¤F
datagovtw.com/company.php?id=50858859
©ÒÀç¨Æ·~¸ê®Æ ¡P ¤ß¬ù¦³¤½¥q
H201010: ¤@¯ë§ë¸ê·~
¥Nªí¤H©m¦W VIVIAN YALING WU
ÁÙ¦³¦pªG¤ß®®n»´ä¤W¥«¡A³]¥ß¤ß¬ù¦³¤½¥q®Ú¥»¦h¦¹¤@Á|
¤½¥q¸³¨Æ¸gÀç°ª¼h³]¥ß§ë¸ê¤½¥q¥Øªº¬OnÂಾ«ùªÑ¸`µ|
»´ä¤@¼Ë¬O¤¤¤å¤S¤£¬O¶·¦³¥~»y¯à¤Oªº^¤å¡A¸ê®Æ«Ü®e©ö§ä¡A¸ê®Æ¤ñ§A¶Kªº¥xÆW·s»D§ó¸Ô²Ó
§A¤£¶K»´ä©x¤è¤@¤â¸ê®Æ¡A³oÓ¶K¥xÆW¤G¤â·s»D
www.hkex.com.hk/News/Market-Consultations/2016-to-Present/February-2018-Emerging-and-Innovative-Sectors?sc_lang=zh-HK
www.hkex.com.hk/-/media/HKEX-Market/News/Market-Consultations/2016-Present/February-2018-Emerging-and-Innovative-Sectors/Consultation-Paper/cp201802_c.pdf
²Ä¤G³¹82±ø³W©wÀç¹B¸êª÷¶·²[»\¥¼¨ÓÀç¹B¶}¤ä¦Ü¤Ö125%
¥t¥~¥xÆW·s»D
money.udn.com/money/story/10161/3304235
¥²¶·¦Ü¤Ö¤@Ó¸g°ê»Ú¥Dn°ê®a»{¥iªºÁ{§É¤G´Á²£«~¡A¦AªÌ¥²¶·¦³¤j³°©Î»´ä±M·~§ë¸ê¤H°Ñ»P¨Ã¦¨¬°¤jªÑªF¡A¥t¥~¡A¥«È¼Ð·Ç¥²»Ý¹F´ä¹ô15»õ©Î2»õ¬ü¤¸
³o¤]´N¬O¤U¦C
www.hkex.com.hk/-/media/HKEX-Market/News/Market-Consultations/2016-Present/February-2018-Emerging-and-Innovative-Sectors/Conclusions-(April-2018)/cp201802cc_c.pdf
85.(a)(iv)
ºÞ²z¸ê²£Á`»ùȤ£¤Ö©ó10»õ´ä¤¸ªº§ë¸êªÌ¡B§ë¸ê°òª÷©Îª÷¿Ä¾÷ºc
¥B¤W¶µ§ë¸ê¤½¥q¶·§ë¸ê¤W¥«®É¤wµo¦æªÑ¥»ªº5%
¤ß®®ªÑªF¨S¦³´ä¸ê©Î¤¤¸ê§a
¥t¥~
²Ä¤G³¹82±ø³W©wÀç¹B¸êª÷¶·²[»\¥¼¨ÓÀç¹B¶}¤ä¦Ü¤Ö125%
²{¦b¤ß®®¸êª÷°÷¶Ü?¥i¥H¼µ¨ì¦Ü¤Ö¨â¦~ªºÀç¹B¨ì»´ä¤W¥«ªºÀç¹B¤@¦~«á¶Ü?
»´ä¤W¥«¤£ª¾n¼f®Ö¦h¤[
¥xÆW§ë¸ê¤H¤S¦h¤Ö¤H¦³@¤ß¯àµ¥¤@¦~
¦Ó¤@¦~¤ß®®«á¤]®t¤£¦h¸Ñª¼¤F¡A¨º¤ß®®¸Ñª¼¬°¤°»ò¤£ª½±µ¦b¥xÆW¤W¥«Âd´N¦n¡AÁÙn¶°é¨ì»´ä±¾µP
¥xÆW¤W¥«Âd¤]¥i¥H¨ì¬ü°êADR
¥H¤ß®®ªº²£«~©Ê½è¬ü°êADR©ÎIPO§ó±µªñ¥«³õ
½²³Õ¤hªø«Ý¬ü°êADR¹ï¬ü°ê§ë¸ê¤H¨S®É®t°ÝÃD¡A·¾³q§ó¦n
¹ï©ó¤½¥q«n·F³¡Âà¥ôSyneuRx Neuroscience HK Ltd.
§Ú¬O²q´ú¤U¤@¶¥¬q¤½¥qn¶}©l¬ãµo¥¢´¼¯g
SND5ì®Æ¨ÑÀ³¤Î¥Í²£¤§±MÄݩʬO©M´ò¥_¤®p¨ª¸Ûñq
±µ¤U¨Ó¶i«×´N¬On¦V¤¤°êCFDA¤Î¬ü°êUS FDA¥Ó½ÐÁ{§É¤G´ÁIND
Ãĵؤ]¦³¦b»´ä³]¥ß¤À¤½¥q
¤£±Æ°£¤ß®®·|¹³Ãĵؤ@¼Ë¡A»´ä³]¥ß¤½¥qªº¥Øªº¬O¥´ºâ¤¤°ê¥«³õ¦Û¤v½æ
¦b [ »´ä¥«³õ²¤¶ ] ¤å¤¤
www.tej.com.tw/twsite/TEJWeb/tw/database/doc/hk.pdf
´£¤Î
¥i±µ¨üªº¥qªk¦a°Ï , ¥]¬A
1. ®Ú¾Ú¡m¤W¥«³W«h¡n¡A©ó»´ä¡B¤¤µØ¤H¥Á¦@©M°ê¡B¶}°Ò¸s®q¤Î¦Ê¼}¹F¦¹¥|Ó¥qªkÅv°Ï¡]¡u»{¥i¥qªkÅv°Ï¡v¡^µù¥U¦¨立ªº¤½¥q²Å¦X´£¥X¤W¥«¥Ó½Ðªº¸ê®æn¨D¡C
2. °£»{¥i¥qªkÅv°Ï¥~¡A聯¥æ©Ò±µ¯Ç 21 Ó¥qªkÅv°Ï¬°¤½¥qµù¥U¦¨立¦a¡]Àò±µ¯Ç¥qªkÅv°Ï¡^¡C
¡iµù 1¡j²{®É¡A¦b聯¥æ©Ò¤W¥«ªº¦w¤j略省¤½¥q¥u¦³¤@®a¡A¬°©ó 1999 年¥Ó½Ð¤W¥«ªº§»利金¿Ä¡]ªÑ¥÷¥N¸¹¡G0945¡^¡A¸Ó¤½¥q¬O¦b 2007 年聯¦X¬Fµ¦Án©ú¤½¥¬«e¤W¥«¡C
¡iµù 2¡j¨ä¾l 20 Ó¥qªkÅv°Ï¤À§O¬°¡G¿D¬w¡B¤Ú¦è¡B^Äݺûº¸¨Ê¸s®q¡B¥[®³¤jªüº¸§B¹F省¡B¥[®³¤j不列ÄAô倫¤ñ¨È省¡B塞®ú路´µ¡Bªk°ê¡B¼w°ê¡B®æ®¦¦è¡B°¨®¦®q¡B·N¤j利¡B¤é¥»¡B¿A¦è®q¡BÁú°ê¡B¯Ç»Ô¡B盧´Ë³ù¡B·s¥[©Y¡B^®æ蘭¤Î«Âº¸´µ¡B¬ü°ê¥[¦{¡B¬ü°ê¯S拉µØ¦{¡C
©Ò¥H , ¤½¥q¥²¶·¦b¤Wz¥qªkÅv°Ïµù¥U , ¤è¯à¦b»´ä¤W¥«
¦]¦¹²q´ú SyneuRx Neuroscience HK Ltd. ©Î¬°¦b»´ä¤W¥«ªº¥DÅ餽¥q
Y¦¹ , ±N¨Ó¥xÆW¤ß®®ªºªÑªF±N¥H´«ªÑªº¤è¦¡ , Âର«ù¦³ SyneuRx Neuroscience HK Ltd. ¦b´ä¥æ©Ò¥æ©ö
±z¥un¨ì¦³½Æ©e°Uªº¥xÆWÃҨ餽¥q , ¶}¥ß½Æ©e°U±b¤á«K¥i¥æ©ö , ¬ÛÃöªºµ|¨î , ½Ð°Ñ¤§«eªº°Q½×©Î¦Û¦ægoogle
¤S¨Ì¸gÀÙ¤é³ø2018/4/25ªº³ø¾É
´ä¶}©ñ¥¼¬Õ§Q¥Í§Þ·~IPO
2018-04-25 01:33¸gÀÙ¤é³ø °OªÌ½²±Ó«º¡þºî¦X³ø¾É
•
money.udn.com/money/story/5604/3105607
. ¦b³Ì·sµo¥¬ªº«t¸ßÁ`µ²¤¤¡A¹ï©óµL¦¬¤J¥Íª«¬ì§Þ¤½¥q¡A´ä¥æ©Ò·s¼W³W©w¡AÀÀ¤W¥«¤½¥q¹w´Á¥«È¤£¤Ö©ó15»õ´ä¤¸¡A¥Bn²Å¦X¦h¶µn¨D¡C¥]¬A±q¨Æ®Ö¤ß²£«~¬ãµo¦Ü¤Ö12Ó¤ë¡B¦Ü¤Ö¦³¤@¶µ®Ö¤ß²£«~¤w¸g³q¹L·§©À¶¥¬q¶i¤J²Ä¤G´Á©Î²Ä¤T´ÁÁ{§É¸ÕÅçµ¥¡C
´ä¥æ©Ò³W©wµLÀ禬¥Í§ÞªÑªº³Ì§CÁ`¥«È¬° 15»õ´ä¤¸
¥H´ä¹ô/¥x¹ô = 4 pºâ , ´«ºâ¥xÆW¤ß®®ªºªÑ»ù ¦Ü¤Ö¦b60¤¸
³o¬O¥H´«ªÑ¤ñ¨Ò ( ¥xÆW¤ß®®/»´ä¤ß®® ) = 1 ¦ôºâªº ( ·íªì©_´º¨ì¬ü°ê±¾µP±Ä¤@ªÑ´«¤@ªÑ )
°²¦p¤½¥q¯àÅé«ò¦b¿³Âd®É´Á¶R¶iªºªÑªF¤j¦h®M¨c©M©Ó¨üªº·Î¼õ¥B¿³Âdªº±¾µP°Ñ¦Ò»ù¹F168 ¤¸
Y¤½¥q¯à¥H¹ï¥xÆW¤ß®®ªÑªF§ó¦³§Qªº´«ªÑ¤ñ¨Ò ( ¤ñ¦p1.2 , 1.5 , ¬Æ©Î2 , 3 ; ·N§Y±N»´ä¤ß®®ªºªÑ¥»©ñ¤j , IPO»ù®æ¥i¥H¤£¥Î±¾¤Ó°ª ) , ·í§@¬O¹ï¥xÆW¤ß®®ªÑªFªº¤@ºØ¸ÉÀv , «h§ó¤£¦b¸Ü¤U
·íµM , ³o©Î·|²o¯A»P»´ä¤W¥«©Ó¿ì¨é°Óªº·¾³q¨ó½ÕIPO»ù®æ , ¦ý¼f«×Á{§Éªº¶i«×¶i®i , ¥¼¹Á¨S¦³¥i¯à
¥xÆW¤£¤Ö¦³¼ç¤Oªº·sÃĪѳQµuµøªºì©lªÑªF·í´£´Ú¾÷ , ªÑ»ù³QÄY«§C¦ô
¦³¹ê¤O©M§Ó®ðªº¤½¥q°ª¼h·í¿³°_¥X¨«©ÀÀY , ¥Ñ±ý¦R´e®ð¶i¦Ó´¬Ü¦R®ð
¤p§Ì´Ü¨Ø¤j®aªº²H©w
²H©wªº¤ß , ©Î¨Ó¦Û©ó¹ï½²±Ð±Âªº«H¥ô©M«H¤ß
¦P®É , «D±`·PÁ¤½¥q¹ï©ó±N¨Ó¤W¥«ªº°Ê¦V¥ýµ¹§Ú̪ѪF´£¥Ü , Åý§Ú̹綠¥q¦h±¡ªº¤ß¨S¦³¿W¦V±I¹æ
³oÓ¨Mµ¦À³¬O¤½¥q¦Ò¶q¦h¤è¦]¯À , ¥H¤½¥qµo®i©MªÑªFÅv¯q¬°¨ÌÂkªº³Ì§´¾A¤è®×
§Ú·Q , ¦b³oÓ®ÉÂI°Ê§@ , ¬O§_¥NªíµÛÁ{§ÉÁͦV¥¿¦Vµo®i ? §_«h¾Ì¬Æ»ò¨ì»´ä¤W¥«¤Þ¸ê ?
¤S«ä¦Ò±¾µP«eªº¤£¥æ©ö´Á , ¬O§_«ê¥i¸ú¹L¬üªÑªº¤£Ã©w´Á ?
¥B·í±¾µP®É , YSND-13¤wªñ¦¨¥\ , ¬Æ©Î¸Ñª¼¦¨¥\
¨º±¾µP»ù©Î±N§ó¦³·Q¹³ªÅ¶¡ ?
«¢ ! ¤ñ°_¥xÆW°h¥X¿³Âdªº»ù®æ , ®M¥yªÑ¥«³N»y --- ©Î¥i¤j´T¸õªÅ¶}°ª ( °²¦p¿³Âd»ù®æ¤´¨S¶i®iªº¸Ü )
§Æ±æ¤ß®®¤½¥qµo®i¶¶§Q¦¨¥\ , ¤]®É®É¥HªÑªFÅv¯q¬°©À , ¬O¬°¦Ü¬ß
¤@´[±¡Ä@²q´úªºÃ¨¤ß¦k·Q , ½Ð¤j®a¬Ý¬Ý´N¦n , ¤Á¤Å·í§ë¸ê¨Ì¾Ú
¨Ã½Ð«ü¾É«ü¥¿
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a !
1.¤HûÅܰʧO¡]½Ð¿é¤Jµo¨¥¤H¡B¥N²zµo¨¥¤H¡B«nÀç¹B¥DºÞ¡B°]°È¥DºÞ¡B
·|p¥DºÞ¡B¬ãµo¥DºÞ©Î¤º³¡½]®Ö¥DºÞ¡^:µo¨¥¤H¡B¥N²zµo¨¥¤H¡B°ÆÁ`¸g²z¤Î°]·|¥DºÞ
2.µo¥ÍÅܰʤé´Á:107/11/28
3.ÂÂ¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:
µo¨¥¤H/ ½²¥É´@ °]·|³¡¸g²z
¥N²zµo¨¥¤H/ ¶À¼yªÛ ¤H¨Æ¦æ¬F³¡¸ê²`¸g²z
°ÆÁ`¸g²z/ ¤ý´º¥¿ °ÆÁ`¸g²z
°]·|¥DºÞ/ ½²¥É´@ °]·|³¡¸g²z
4.·s¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:
µo¨¥¤H/ «¸§Ó¿« °ÆÁ`¸g²z
¥N²zµo¨¥¤H/ ÃC©É¯u ½]®Ö«Ç¸g²z
°]·|¥DºÞ/ ¬ö©{§D °]·|³¡°Æ²z
5.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¾°È½Õ¾ã¡v¡B¡u¸ê»º¡v¡B¡u°h¥ð¡v¡B¡u¦º¤`¡v©Î¡u·s
¥ô¡v¡^:Ãã¾
6.²§°Êì¦]:
½²¥É´@¸g²zÃã¥ô¥»¤½¥qµo¨¥¤Hº[°]·|¥DºÞ¡AÂà¥ôSyneuRx Neuroscience HK Ltd.¤½¥q¡C
¶À¼yªÛ¸g²zÃã¥ô¥»¤½¥q¥N²zµo¨¥¤H¡AÂà¥ô¤ß¼Ö¥ÍÂ妳¤½¥q¡C
¤ý´º¥¿°ÆÁ`¸g²zÃã¥ô¥»¤½¥q°ÆÁ`¸g²z¡AÂà¥ôSyneuRx Neuroscience HK Ltd.¤½¥q¡C
7.¥Í®Ä¤é´Á:107/11/28
8.·s¥ôªÌÁpµ¸¹q¸Ü:02-77422699
9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¼È¥Ñ¥»¤½¥q°]·|°Æ²z¬ö©{§D¥N²z°]·|¥DºÞ¡A«S³Ìªñ´Á¸³¨Æ·|¨Mij
³q¹L·s¥ô°]·|¥DºÞ¸u¥Î®×«á¦A¦æ¤½§i¡C
¶³¹L¤sÀYı¤Ñ§C ±ýµn®p¤WIJ¥i¤Î
ÂQ©¹¤Ñ¥~µL·³¤ë ¤£p¤µ´Â¬O´X®É
...²H©wing
¬ìºÍ°ß¦w¡]Clarivate Analytics¡^ 2018-11-25
ì¤å§@ªÌ¡GJamie Munro & Helen Dowden
¤¤¤å½Ķ¡GÀxÌɵØ
med.sina.cn/article_detail_103_2_56449.html
³Ìªñ¤¦~¨Ó¡A¾¨ºÞ¬Û¹ï¨Ó»¡¡A¨u¨£¯f¦p¹B°Ê¯«¸g¤¸¯e¯f¡A¥H¤Î¸£¦åºÞ¯e¯f©M¸£·l¶Ëµ¥¯e¯fªº¥æ©ö¥X²{¤F§ó¤j´T«×ªº¼Wªø¡A¦ý¯kµh©Mªüº¸¯÷®üÀq¯g¬ÛÃöªº¥æ©ö¥¿¦b¼W¥[¡C¦¹¥~¡A¤@¨Ç¨à¬ìºë¯«¯e¯f¡A¦p¦Û³¬¯g©M¹p¯Sºî¦X¼xªº¥æ©ö¬¡°Ê¤]¦³©Ò¼W¥[¡CµM¦Ó¡AÁöµMÅöíw©Mºë¯«¤Àµõ¯g³o¨âºØ¯e¯f¨Ã¨S¦³±o¨ì«Ü¦nªº±±¨î¡A¦ý¬ÛÃöªº¥æ©ö¼Æ¶q¦b³o¬q®É¶¡¸Ì¥X²{¤F©úÅ㪺¤U°¡]¹Ï1b¡^¡C
¬°¦ó¦b«äı¥¢½Õ»â°ìªñ¦~¨Ó¥æ©ö¼Æ¶q§e²{©úÅã¤U°¡H
©Î¦]¨S¦³«GÂI·sÃÄ¡H
«äı¥¢½Õ»â°ì¥¿¦V¯gª¬ÃĪ«¤w§e¾ÖÀ½¡A¤j¼t©Î±N¥Ø¥úª`µø¦bt¦V¯gª¬¤Î»{ª¾³o¨â¶µ¥¼³Qº¡¨¬ªº»â°ì
¥¿¦]¬°¦¹
Åý¤H¹ïSND-11; 12; 13±H¤©«p±æ¡I¡H
§Æ±æ 2b+3 ´ÁÁ{§ÉªºÃĮįà¦p 2a ´Á£¸¼Ë«GÄR¡A¾P°â©Î±N¥i´Á«Ý
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a ¡I
¨Ó·½¡G°Ê¯ßºô ¡@2018-11-23
§@ªÌ¡GMailman
med.sina.com/article_detail_103_2_56397.html
ªñ¤é¡AAllied Market Researchµo¥¬¤F¤@½g¦W¬°¡m§íÆ{¯gÃĪ«¥«³õ§íÆ{¯g¡]«©Ê§íÆ{¯g¡B±j¢¯g¡B¼sªx©ÊµJ¼{¯g¡B®£·W¯gµ¥¡^©M²£«~¡]¤TÀôÃþ§Ü§íÆ{ÃÄ¡B¿ï¾Ü©Ê5-ßm¦âÓi¦AÄá¨ú§í»s¾¯¡B5-ßm¦âÓi¥h¥ÒµÇ¤W¸¢¯À¦AÄá¨ú§í»s¾¯¡B³æÓi®ñ¤Æ酶§í»s¾¯¡B5-ßm¦âÓi«ú§Ü¾¯©M¦AÄá¨ú§í»s¾¯¤Î¨ä¥L¡^¡G¥þ²y¾÷·|¤ÀªR©M¦æ·~¹w´ú¡A2017-2023¡nªº¤å³¹¡C¤å³¹Åã¥Ü¹wp¨ì2023¦~¥þ²y§Ü§íÆ{ÃĪ«¥«³õ±N¹F¨ì159.8»õ¬ü¤¸¡A¹w´ú´Á¤º´_¦X¦~¼Wªø²v¬°2.1¢H¡A°Ê¯ßºô¬°±z½sĶ¤F¸Ó¤å³¹ªº¥DÃD¤º®e¡G
¸Ó³ø§i³q¹L¦æ·~ÁͶաBÅX°Ê¦]¯À©M¾÷¹J¡BÃöÁä¼Wªøµ¦²¤¥H¤ÎÄvª§®æ§½¡A¹ï¥þ²y§Ü§íÆ{ÃÄ¥«³õ¶i¦æ²`¤J¤ÀªR¡C®Ú¾Ú¸Ó³ø§i¡A2017¦~¥þ²y§Ü§íÆ{ÃĪ«¥«³õ¬°141.1»õ¬ü¤¸¡A¹wp¨ì2023¦~±N¹F¨ì159.8»õ¬ü¤¸¡A¹w´ú´Á¤º´_¦X¦~¼Wªø²v¬°2.1¢H¡C
¬JµM brexanolone ¦³ ÀH³X´Á¶¡ªº¦Û±þ·N©À
¬O§_¤]¥NªíµÛ SAGE-217 ¤]¦³³oºØ°Æ§@¥Î ?
¤j®a¦³½Öª¾¹D¶Ü?
½Ð¤£§[¤À¨É
ÁÂÁ¤j®a!
¨Ó·½¡GÂåÃÄÅ]¤è ¡@2018-11-23
§@ªÌ¡G«C¥Ë
med.sina.com/article_detail_103_2_56378.html
¦b¬ü°ê¡AFDA¤w±Â¤©brexanoloneªvÀø²£«á§íÆ{ªº¬ð¯}©ÊÃĪ«¸ê®æ¡A¦b¼Ú·ù¡AEMA¤]¤w±Â¤©Àu¥ýÃĪ«¸ê®æ¡]PRIME¡^¡C
¥u¬O¸ÓÃĪ«ªº¨Ï¥Îµ¹¤©60¤p®ÉÀR¯ß¿éª`ªº±wªÌ¡An¨D±wªÌ©M´£¨ÑªÌ©Ó¿Õªø´ÁªºÁ{§É¿éª`¡C
Brexanolone¬O¬ðIJ©M¬ðIJ¥~£^-®ò°ò¤B»ÄA «¬¨üÅé¡]GABAA ¨üÅé¡^ªºÅܺc½Õ¸`¾¯¡CGABAA¨üÅé©MNMDA¡]N-methyl-D-aspartate¡^¨üÅé¤À§O°_¨ì§í¨î©M¨ë¿E¤j¸£¯«¸g¤¸²£¥Í¯«¸g½Ä°Êªº§@¥Î¡C³o¨âºØ¨üÅ鬡©Ê¤§¶¡ªº¥¢¿Å¬O¥]¬A§íÆ{¯g¦b¤ºªº¦hºØºë¯«¯e¯fªºì¦]¡C
³Ì±`¨£ªºbrexanoloneªvÀø¬ÛÃö¤£¨}¨Æ¥ó¬°ÀYµh¡BÀY©ü¡B¶ÝºÎ¡Aµo¥Í4¨ÒªvÀø¬ÛÃöªºÄY«¤£¨}¨Æ¥ó¡A¥]¬AÀH³X´Á¶¡¦Û±þ·N©À¡B¬G·NÃĪ«¹L¶q¡B·NÃѪ¬ºA§ïÅÜ»P·w³Ö¡C
¥þ²y³Ì¤ûMRI¡I¥i¬Ý¨ì¤j¸£©Ò¦³²Ó¸`
¨Ó·½¡GÁɬfž¹±ñ ¡@2018-11-12
¨Ó·½¡Gºî¦X¦ÛNature©xºô¡BÂå¾Ç¬É¾ã²z¡GÁɬfž¹±ñ
med.sina.com/article_detail_103_1_55679.html
¨Ó·½¡G³ÐŲ¶× ¡@2018-11-11
med.sina.com/article_detail_108_1_55659.html
¨ä¤¤¦³Ãöºë¯«¯«¸g»â°ìªº¦³:
¤½¥q¦WºÙ¡GDenali Therapeutics»PTakeda
¥æ©öª÷ÃB¡G10»õ¬ü¤¸
¦X§@»â°ì¡G¯«¸g°h¦æ©Ê¯e¯f
¤½¥q¦WºÙ¡GIndivior»PAddex Therapeutics
¥æ©öª÷ÃB¡G3.3»õ¬ü¤¸
¦X§@»â°ì¡GÃĪ«¦¨Å}
¤½¥q¦WºÙ¡GKineta»Pù¤ó¶°¹Î¡]Roche Group¡^¦¨û°ò¦]®õ§J¡]Genentech¡^
¥æ©öª÷ÃB¡G3.6»õ¬ü¤¸
¦X§@»â°ì¡G«Dªü¤ùÃþ¤î¯kÃÄ
¤½¥q¦WºÙ¡G¦Ê°·¡]Biogen¡^¤½¥q©MIonis Pharmaceuticals
¥æ©öª÷ÃB¡G10»õ¬ü¤¸
¦X§@»â°ì¡G¯«¸g¯e¯f·sÃÄ
¤½¥q¦WºÙ¡GSage Therapeutics»PÆQ³¥¸q»sÃÄ¡]Shionogi¡^
¥æ©öª÷ÃB¡G5.75»õ¬ü¤¸
¦X§@»â°ì¡G§Ü§íÆ{ÃÄ
¤½¥q¦WºÙ¡GDenali Therapeutics»PÁÉ¿Õµá¡]Sanofi¡^
¥æ©öª÷ÃB¡G10»õ¬ü¤¸
¦X§@»â°ì¡G¯«¸g¨t²Î¯e¯f·sÃÄ
¸Ô±¡½Ð°Ñì¤å³sµ²
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¤º³¡¤H«ùªÑ²§°Ê¨Æ«á¥Ó³øªí
¤w¸g¦³¤½§i¤F~§Æ±æ¤½¥q¦n®ø®§¶V¨Ó¶V¦h~
¤½¥q¤jªÑªF«ùÄò¼W¥[«ùªÑ...
¤º³¡¤HÃö«Y¤H«ùªÑ¥Ñ620±i..10¤ë©³¸ê®Æ¼W¥[¦Ü930±i...
°]°È³¡ªù¥DºÞ10¤ë©³«ùªÑ¥Ó³ø¼W¥[23±i...
¥H¤W~¨Ñµ½¨}.´¼¼z¤§ªø½u§ë¸ê¾Ô¤Ḭ́ѦÒ~~
www.genetinfo.com/investment/featured/item/21113.html?start=1
¨Ó·½¡G ¥Íª«¨¦ ¡@2018-11-06
med.sina.com/article_detail_103_1_55369.html
ALKS5461¬O¤@ºØ¨C¤é¤@¦¸ªº¤fªAÃĪ«¡A¦®¦b«·s¥¿Å§íÆ{¯g±wªÌ¤j¸£ªº¥\¯à¥¢½Õ¡A¸ÓÃĨ㦳¤@ºØ·s¿oªº§@¥Î¾÷¨î¡A¦pªGÀò§å¡A±N¦¨¬°·s¤@Ãþªº§Ü§íÆ{ÃĪ«¡A§Y¤j¸£¤º·½©Êªü¤ù¨t²Î½Õ»s¾¯¡C¤j¸£ªü¤ù¨t²Î¬O¤HÃþ±¡·P©M±¡ºüªº¤@ÓÃöÁä½Õ¸`¨t²Î¡C¥Ø«e¡AALKS5461¥¿¶}µo§@¬°¤@ºØ»²§UªvÀøÃĪ«¡A¥Î©ó¹ï¼Ð·Çªº§Ü§íÆ{Àøªk¤ÏÀ³¤£¨¬ªº««×§íÆ{¯g¡]MDD¡^±wªÌ¡C
ALKS5461¥Ñ©T©w¾¯¶qªº¤B¤þ¿Õ°Ø©Msamidorphan¡]ALKS-33¡^²Õ¦¨¡A¨ä¤¤¤B¤þ¿Õ°Ø¬O¤@ºØ£g-ªü¤ù¨üÅ鳡¤À¿E°Ê¾¯©M¥\¯à©Êk-ªü¤ù¨üÅé«ú§Ü¾¯¡A¨ã¦³¦¨Å}·ÀI
Alkermes¤½¥q¤§«e¹wp¡A¦pªG¦¨¥\Àò§å¤W¥«¡AALKS5461¦³±æ¦¨¬°¤@´Ú«½SÃĪ«¡C¤µ¦~2¤ëµo¥¬ªº2017°]¦~³ø§i¤¤¡A¸Ó¤½¥qªí¥Ü¡A¹wpFDA¦b¨ü²zNDA¤§«á·|¥[³t¼f¬d¡A¨Ã¦b¤µ¦~¤U¥b¦~§åãALKS5461¡C¤£¹L¡A±q¥Ø«e±¡ªp¨Ó¬Ý¡A¸Ó¤½¥qªº«½S´Á±æ«Ü¦³¥i¯àn¸¨ªÅ¤F¡C
¨Ó·½¡GÃÄ©ú±d¼w¡@
2018-11-06
med.sina.com/article_detail_100_2_55332.html
¤é«e¡ASage Therapeutics¤½¥q«Å¥¬¡AFDA¿Ô¸ß©eû·|¥H17:1ªº§ë²¼µ²ªG¡A±ÀÂËFDA§åã¸Ó¤½¥q¬ãµoªº¥Î©óªvÀø²£«á§íÆ{¯g¡]PPD¡^ªºZulresso¡]brexanolone¡^¤W¥«¡C¦pªGÀò±o§åã¡A³o±N¬O²Ä¤@´Ú°w¹ïPPDªºÀò§åÃĪ«¡C
Zulresso¬OSage¤½¥q¬ãµoªº¤@ºØGABA-A¨üÅéÅܺc½Õ¸`¾¯¡C¹ï¯«¸g»¼½è¨üÅ骺Åܺc½Õ¸`¯à°÷±N¨üÅ鬡©Ê½Õ¸`¨ì¤£¦Pªº¤ô¥¡A¦Ó¤£¬O§¹¥þ¿E¬¡©ÎªÌ§í¨î³o¨Ç¨üÅé¡CZulresso¤w¸gÀò±o¤FFDAªº¬ð¯}©ÊÀøªk»{©w©M¼Ú¬wÃÄ«~ºÞ²z§½ªºPRIMEÃÄ«~»{©w¡C
FDA¦b¤µ¦~5¤ë30¤é±µ¨ü¤FZulressoªº·sÃĥӽС]NDA¡^¨Ã¥B±Â¤©¨äÀu¥ý¼fµû¸ê®æ¡C³o·N¨ýµÛ¸ÓÃĪ«¦³±æ¦b¤µ¦~12¤ë19¤é¥H«eÀò±o§åã¡A¬°¨ü¨ìPPD§xÂZªº¶ý¶ýÌÄm¤W¤@¥÷¸t½Ï§ª«¡C
¨Ó·½¡GÃÄ©ú±d¼w¡@2018-11-02
med.sina.com/article_detail_100_2_55180.html
¤µ¤é¡A±Mª`©ó¶}µoªvÀø¯«¸g°h¦æ©Ê¯e¯fÃĪ«ªº¥Íª«ÂåÃĤ½¥qDenali Therapeutics«Å¥¬±N»PÁÉ¿Õµá¡]Sanofi¡^¦X§@¶}µo¦hºØRIPK1¡]¨üÅé¬Û¤¬§@¥Îµ·®ò»Ä/Ĭ®ò»Ä-³J¥Õ¿E酶1¡^§í»s¾¯¤À¤l¡A¥Î©óªvÀø¤@¨t¦C¯«¸g¨t²Î¯e¯f©M¥þ¨ª¢¯g©Ê¯e¯f¡C
¨ä¤¤¨âºØÔ¿ï¤À¤lDNL747©MDNL758¦®¦b¹v¦VTNF¨üÅé³q¸ô¤¤ªºÃöÁä«H¸¹³J¥ÕRIPK1¡A³oºØ³J¥Õ¯à½Õ¸`¥þ¨²Õ´¤¤ªºª¢¯g©M²ÓM¦º¤`¡C¦X§@Âù¤èp¹º¬ã¨sDNL747ªvÀøªü¯÷®üÀq¯f¡B¦ÙµäÁY°¼¯Áµw¤Æ¯g¡]ALS¡^©M¦hµo©Êµw¤Æ¯g¡]MS¡^ªº®ÄªG¡A¥H¤ÎDNL758ªvÀø¥þ¨ª¢¯g©Ê¯e¯f¡]¨Ò¦pÃþ·Àã©ÊÃö¸`ª¢©M»È®h¯f¡^ªº®ÄªG¡C
®Ú¾Ú¨óij±ø´Ú¡AÁÉ¿Õµá±N¦VDenali¤ä¥I1.25»õ¬ü¤¸ªº¹w¥I´Ú¡A¥H¤Î¥¼¨Ó¥i¯à¶W¹L10»õ¬ü¤¸ªº¶}µo©M±À¼s¨½µ{¸O¥I´Ú¡CÁÉ¿Õµá©MDenali±N¦@¨ÉDNL747¦b¬ü°ê©M¤¤°ê±À¼sªº¦¬¯q©M·ÀI¡A¦ÓDenali±NÀò±oDNL747¦b¨ä¥L¦a°Ï©MDNL758¦b¥þ²yªº¾P°â¤À¦¨¡C